Study on the Effects of Epinephrine, Vasopressin, and Methylprednisolone in Cardiac Arrest Patients

3 1 1 1

What is this study about?

This clinical trial is focused on studying the effects of a combination of medications on patients experiencing a cardiac arrest, which is a sudden stop in heart function. The medications being tested include adrenaline (also known as epinephrine), vasopressin (also known as argipressin), and steroids such as methylprednisolone and hydrocortisone. These medications are administered through an injection directly into the bloodstream.

The purpose of the study is to determine if using this combination of medications can improve the chances of survival 30 days after a cardiac arrest, compared to using adrenaline alone. Participants in the study will receive either the combination of medications or the standard treatment with adrenaline. The study will monitor the participants over a period to assess their survival and recovery.

Throughout the study, participants will be closely observed by medical professionals to ensure their safety and to gather data on the effectiveness of the treatment. The study aims to provide valuable insights into improving treatment outcomes for cardiac arrest patients.

1 joining the trial

Upon joining the trial, you will be informed about the study’s purpose, which is to determine if a combination of medications can improve survival after a cardiac arrest.

You will be asked to provide consent to participate in the study, acknowledging that you understand the procedures and potential risks involved.

2 initial treatment

If you experience a cardiac arrest while in the hospital, you will receive the standard treatment, which includes the administration of adrenaline.

In addition to adrenaline, you may receive a combination of other medications: vasopressin and steroids.

3 medication administration

The medications will be given to you through an intravenous route, meaning they will be injected directly into your bloodstream.

The specific medications used in the trial are methylprednisolone, epinephrine (another name for adrenaline), argipressin (another name for vasopressin), and hydrocortisone (a type of steroid).

4 monitoring and follow-up

After receiving the treatment, your health will be closely monitored by medical professionals to assess your response to the medications.

The primary goal is to evaluate your survival at 30 days after the cardiac arrest event.

5 completion of the trial

The trial is expected to continue until February 27, 2025, with recruitment having started on March 15, 2022.

Your participation will contribute to understanding the effectiveness of the treatment in improving survival rates after cardiac arrest.

Who Can Join the Study?

  • Patients who have experienced a cardiac arrest while in the hospital. A cardiac arrest is when the heart suddenly stops beating.
  • Patients who need to receive adrenaline as part of their treatment, according to the current guidelines from the European Resuscitation Council (ERC). Adrenaline is a medication used to help restart the heart.
  • Both men and women can participate in the study.
  • Participants must be within the specified age range for the study, which includes adults and older adults.

Who Cannot Join the Study?

  • Patients who have experienced a cardiac arrest cannot participate. A cardiac arrest is when the heart suddenly stops beating.
  • Patients who are under the age of 18 or over the age of 65 cannot participate.
  • Patients who are pregnant or breastfeeding cannot participate.
  • Patients with a history of severe allergic reactions to any of the study medications cannot participate.
  • Patients who are currently participating in another clinical trial cannot participate.
  • Patients with any other medical condition that the study doctors believe would make it unsafe for them to participate cannot participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Sahlgrenska University Hospital Gothenburg Sweden
Soedersjukhuset AB Stockholm Sweden
Tsavglsaj At Norrtalje Sweden

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Sweden Sweden
Not recruiting
15.03.2022

Trial locations

Adrenaline is a medication that is often used in emergency situations to help restart the heart when it has stopped beating. It works by increasing blood flow to the heart and helping the heart to pump more effectively. In this trial, adrenaline is being used as a standard treatment for cardiac arrest.

Vasopressin is another medication used in this trial. It helps to increase blood pressure by narrowing blood vessels, which can be beneficial during a cardiac arrest. By doing this, vasopressin can help improve blood flow to vital organs, including the heart and brain, during an emergency.

Steroids are a type of medication that can reduce inflammation and affect the immune system. In the context of this trial, steroids are being used to see if they can improve survival rates in cardiac arrest patients when combined with adrenaline and vasopressin. They may help by reducing inflammation and improving the body’s response to the stress of cardiac arrest.

Investigated diseases:

Cardiac arrest – Cardiac arrest is a sudden loss of heart function, leading to a cessation of blood flow to the body’s organs. It occurs when the heart’s electrical system malfunctions, causing an irregular heartbeat or stopping the heart entirely. This condition can happen without warning and requires immediate medical attention. During cardiac arrest, the brain and other vital organs are deprived of oxygen, which can lead to unconsciousness. If not promptly addressed, it can result in severe damage to the body’s tissues. The progression of cardiac arrest is rapid, necessitating urgent intervention to restore normal heart function.

Trial ID:
2022-500137-89-00
NCT ID:
NCT05139849
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Study on Levosimendan for Improving Survival in Patients with Out-of-Hospital Cardiac Arrest During CPR

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden
  • Study of anti-seizure drug combination in comatose patients with status epilepticus after cardiac arrest

    Recruiting

    3 1 1 1
    Investigated diseases:
    Belgium The Netherlands